Astragaloside IV Inhibits NF-κB Activation and Inflammatory Gene Expression in LPS-Treated Mice

Figure 2

AS-IV inhibits LPS-induced inflammatory gene expression in mouse lung. Mice were randomly assigned to 4 groups as follows: (i) control animals received daily i.p. injection of the vehicle HBSS for 6 days followed by a single i.p. HBSS injection; (ii) AS-IV-treated animals received 10 mg/kg b.w. AS-IV daily i.p. for 6 days followed by a single i.p. HBSS injection; (iii) LPS-treated animals received daily i.p. injection of vehicle HBSS for 6 days followed by a single i.p. injection of 0.5 μg/g b.w. LPS; and (iv) AS-IV plus LPS-treated animals received AS-IV daily i.p. for 6 days followed by single i.p. injection of LPS. Three hours after the HBSS or LPS injection, the animals were sacrificed and tissues were collected. Total RNA was isolated from lung. Inflammatory gene expression was quantified using real-time quantitative PCR. After normalization to the internal control gene GAPDH, the results for each target gene were expressed as percentage of GAPDH. Data shown are means ± SEM of 5 animals per group. compared to animals treated with LPS only.

(a)

(b)

(c)

(d)